Reck, Martin
Mellemgaard, Anders
von Pawel, Joachim
Gottfried, Maya
Bondarenko, Igor
Cheng, Ying
Zarogoulidis, Kostas
Luft, Alexander
Bennouna, Jaafar
Barrueco, José
Aboshady, Hesham
Hocke, Julia
Kaiser, Rolf
Douillard, Jean-Yves
Clinical trials referenced in this document:
Documents that mention this clinical trial
Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer
https://doi.org/10.1016/j.lungcan.2010.08.018
Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer
https://doi.org/10.1016/j.ejca.2014.11.015
Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel
https://doi.org/10.1016/j.lungcan.2015.08.003
Funding for this research was provided by:
Boehringer Ingelheim
This article is maintained by: Elsevier
Article Title: Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel
Journal Title: Lung Cancer
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.lungcan.2015.08.003
Content Type: article
Copyright: Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.